UBS Group’s Integra LifeSciences IART Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.48M | Sell |
138,320
-64,425
| -32% | -$901K | ﹤0.01% | 4911 |
|
|
2026
Q1 | $1.91M | Sell |
202,745
-206,224
| -50% | -$2.26M | ﹤0.01% | 5016 |
|
|
2025
Q4 | $5.08M | Buy |
408,969
+277,745
| +212% | +$3.69M | ﹤0.01% | 4011 |
|
|
2025
Q3 | $1.88M | Sell |
131,224
-66,400
| -34% | -$910K | ﹤0.01% | 5014 |
|
|
2025
Q2 | $2.42M | Sell |
197,624
-31,318
| -14% | -$455K | ﹤0.01% | 4617 |
|
|
2025
Q1 | $5.03M | Buy |
228,942
+80,474
| +54% | +$1.89M | ﹤0.01% | 3765 |
|
|
2024
Q4 | $3.37M | Buy |
148,468
+69,064
| +87% | +$1.51M | ﹤0.01% | 4221 |
|
|
2024
Q3 | $1.44M | Buy |
79,404
+47,087
| +146% | +$1.09M | ﹤0.01% | 4302 |
|
|
2024
Q2 | $942K | Sell |
32,317
-8,162
| -20% | -$242K | ﹤0.01% | 4472 |
|
|
2024
Q1 | $1.43M | Buy |
40,479
+14,648
| +57% | +$586K | ﹤0.01% | 4270 |
|
|
2023
Q4 | $1.12M | Sell |
25,831
-7,634
| -23% | -$300K | ﹤0.01% | 4396 |
|
|
2023
Q3 | $1.28M | Buy |
33,465
+29,538
| +752% | +$1.24M | ﹤0.01% | 3869 |
|
|
2023
Q2 | $162K | Sell |
3,927
-347
| -8% | -$16.7K | ﹤0.01% | 5624 |
|
|
2023
Q1 | $245K | Sell |
4,274
-4,236
| -50% | -$239K | ﹤0.01% | 5232 |
|
|
2022
Q4 | $477K | Sell |
8,510
-14,071
| -62% | -$716K | ﹤0.01% | 4751 |
|
|
2022
Q3 | $956K | Buy |
22,581
+9,109
| +68% | +$467K | ﹤0.01% | 3782 |
|
|
2022
Q2 | $728K | Sell |
13,472
-1,286
| -9% | -$77.2K | ﹤0.01% | 3986 |
|
|
2022
Q1 | $948K | Sell |
14,758
-26,723
| -64% | -$1.76M | ﹤0.01% | 4152 |
|
|
2021
Q4 | $2.78M | Buy |
41,481
+7,993
| +24% | +$541K | ﹤0.01% | 3440 |
|
|
2021
Q3 | $2.29M | Sell |
33,488
-7,612
| -19% | -$538K | ﹤0.01% | 3463 |
|
|
2021
Q2 | $2.81M | Buy |
41,100
+16,800
| +69% | +$1.19M | ﹤0.01% | 3248 |
|
|
2021
Q1 | $1.68M | Sell |
24,300
-9,423
| -28% | -$638K | ﹤0.01% | 3750 |
|
|
2020
Q4 | $2.19M | Sell |
33,723
-8,714
| -21% | -$469K | ﹤0.01% | 3332 |
|
|
2020
Q3 | $2M | Buy |
42,437
+37,631
| +783% | +$1.79M | ﹤0.01% | 3038 |
|
|
2020
Q2 | $226K | Sell |
4,806
-1,082
| -18% | -$53.2K | ﹤0.01% | 4722 |
|
|
2020
Q1 | $263K | Sell |
5,888
-52,445
| -90% | -$2.75M | ﹤0.01% | 4502 |
|
|
2019
Q4 | $3.4M | Buy |
58,333
+40,089
| +220% | +$2.39M | ﹤0.01% | 2991 |
|
|
2019
Q3 | $1.1M | Buy |
18,244
+12,751
| +232% | +$760K | ﹤0.01% | 3887 |
|
|
2019
Q2 | $307K | Sell |
5,493
-26,254
| -83% | -$1.35M | ﹤0.01% | 4645 |
|
|
2019
Q1 | $1.77M | Sell |
31,747
-718
| -2% | -$36.6K | ﹤0.01% | 3089 |
|
|
2018
Q4 | $1.46M | Sell |
32,465
-6,542
| -17% | -$359K | ﹤0.01% | 3341 |
|
|
2018
Q3 | $2.57M | Buy |
39,007
+21,669
| +125% | +$1.35M | ﹤0.01% | 3000 |
|
|
2018
Q2 | $1.12M | Buy |
17,338
+3,755
| +28% | +$233K | ﹤0.01% | 3690 |
|
|
2018
Q1 | $751K | Sell |
13,583
-31,903
| -70% | -$1.67M | ﹤0.01% | 3930 |
|
|
2017
Q4 | $2.18M | Sell |
45,486
-22,610
| -33% | -$1.11M | ﹤0.01% | 3122 |
|
|
2017
Q3 | $3.44M | Buy |
68,096
+9,503
| +16% | +$488K | ﹤0.01% | 2572 |
|
|
2017
Q2 | $3.19M | Buy |
58,593
+5,200
| +10% | +$248K | ﹤0.01% | 2557 |
|
|
2017
Q1 | $2.25M | Sell |
53,393
-5,177
| -9% | -$221K | ﹤0.01% | 2841 |
|
|
2016
Q4 | $2.51M | Buy |
58,570
+43,960
| +301% | +$1.79M | ﹤0.01% | 2711 |
|
|
2016
Q3 | $603K | Sell |
14,610
-4,160
| -22% | -$174K | ﹤0.01% | 3787 |
|
|
2016
Q2 | $749K | Buy |
18,770
+8,054
| +75% | +$290K | ﹤0.01% | 3607 |
|
|
2016
Q1 | $362K | Buy |
10,716
+1,588
| +17% | +$49.5K | ﹤0.01% | 4028 |
|
|
2015
Q4 | $309K | Sell |
9,128
-3,768
| -29% | -$118K | ﹤0.01% | 4329 |
|
|
2015
Q3 | $384K | Buy |
12,896
+380
| +3% | +$11.9K | ﹤0.01% | 4120 |
|
|
2015
Q2 | $345K | Buy |
12,516
+912
| +8% | +$24.3K | ﹤0.01% | 4409 |
|
|
2015
Q1 | $292K | Buy |
11,604
+3,805
| +49% | +$89.9K | ﹤0.01% | 4578 |
|
|
2014
Q4 | $173K | Buy |
+7,799
| New | +$158K | ﹤0.01% | 5174 |
|
Other funds holding IART
RCMNY
PCMI
UBS Group's IART Position: Q2 2026 in Review
UBS Group reduced its Integra LifeSciences (IART) stake by 32% in Q2 2026, selling an estimated $901K and leaving 138,320 shares worth $2.48M. The position accounts for ﹤0.01% of the portfolio, ranked #4911.
UBS Group first reported a position in IART in Q4 2014 and has held it in 47 quarters since. The position peaked at $5.08M in Q4 2025. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.
- UBS Group held 138,320 shares of Integra LifeSciences worth $2.48M as of Q2 2026.
- UBS Group sold 64,425 Integra LifeSciences shares in Q2 2026, an estimated $901K.
- Integra LifeSciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4911 holding.
- UBS Group first reported a position in Integra LifeSciences in Q4 2014 and has held it in 47 quarters since.
- UBS Group's Integra LifeSciences position peaked at $5.08M in Q4 2025.
- 212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.